News | Clinical Study | September 12, 2017

Late-breaking Trial Presentations at ESC 2017

ESC Congress 2017 held Aug. 26-30 in Barcelona, Spain
 

ESC 2017 late breaking trial hot line study presentations.

September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinical Trial presentations highlighting the latest cardiovascular science. ESC 2017 includes 21 late-reaking clinical trials, presented and discussed in four Hot Line sessions, plus late breaking results from 12 registries and 12 clinical trial updates. Some of the key presentations with links to the article were:

• SPYRAL HTN-OFF MED Study: Results Show Efficacy, Safety of Renal Denervation

CASTLE-AF Study: Results Indicate Catheter Ablation of Atrial Fibrillation as First-Line Treatment for Heart Failure Patients

• CANTOS Trial: Designed to directly test the inflammatory hypothesis of atherothrombosis by randomly allocating post-myocardial infarction patients to one of three doses of canakinumab (a monoclonal antibody targeting interleukin 1-beta) or to placebo. 

• DETO2X-AMI: This registry-based randomized clinical trial done in 35 hospitals across Sweden examines if giving oxygen to patients with myocardial infarction is useful or if it actually does harm.

• COMPASS Trial: This study looks whether rivaroxaban, either alone or with aspirin, is superior to aspirin alone for the prevention of myocardial infarction, stroke and cardiovascular death in patients with stable coronary or peripheral artery disease.
 

EMANATE Trial: This study looks at apixaban versus conventional therapy in anticoagulation-naive patients with atrial fibrillation undergoing cardioversion.
 
LAACS Study: This randomized study examined whether surgical closure of the left atrial appendage (LAA) during open heart surgery protects the brain against thromboembolic damage.
 
VIVA Trial: Results of this study will reveal the mortality impact and cost-effectiveness of combined screening for abdominal aortic aneurysm (AAA), peripheral artery disease (PAD) and hypertension.
 
Phase II ORION 1 Trial: Looks at the impact of single or multiple injections of the first-in-class PCSK9 inhibitor inclirisan on low-density lipoprotein cholesterol . The study looked at establishing the dose and dosing frequency that will be required in phase III trials.
 
FOURIER Trial: This clinical trial update will show the efficacy and safety of evolocumab added to high-intensity or moderate-intensity statin therapy in patients with clinically evident atherosclerotic cardiovascular disease.

PURE Trial: Results will reveal the dose-response effect of fruit, vegetable and legume intake on cardiovascular disease  and mortality among 135,335 people aged 35 to 70 without prior cardiovascular disease from 18 countries on five continents.

CLARIFY Trial: Findings from the prospective international longitudinal registry of 32,703 outpatients with stable coronary artery disease will explain how low diastolic blood pressure and increased pulse pressure contribute to the J curve in hypertensive patients with coronary artery disease.

 

Other Key ESC 2017 Presentations

• MobiusHD Device Shows Promise in Treatment of Resistant Hypertension

• Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial

• Real-World Analysis Compares Safety, Effectiveness of Apixaban Versus Warfarin
 

 

 

For more information: www.escardio.org

 

Late-breaking Trials From TCT, ACC, SCAI and HRS: 

SCAI 2017 Late-Breaking Clinical Trial Presentations

Heart Rhythm Society 2017 Late-Breaking Electrophysiology Trials

ACC 2017 Late-Breaking Trials

TCT 2016 Late-breaking Trials and First Reports

Related Content

BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies| September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
News | Vena Cava Filters| September 26, 2017
September 26, 2017 — The one-year results of the SENTRY...
Treatment of Heart Attack Patients Depends on Cancer History
News | Cardio-oncology| September 26, 2017
Treatment of heart attack patients depends on their history of cancer, according to research published recently in...
CardiAMP Heart Failure Trial Design Presented at Texas Heart Institute Symposium
News | Heart Failure| September 25, 2017
BioCardia Inc. announced the trial design for its pivotal Phase III CardiAMP Heart Failure Trial was presented during...
Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Overlay Init